Pharmaceutical

Company News

OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announces that OncBioMune Chief Executive Officer Dr. Jonathan Head will be making an abstract poster presentation today at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival.

OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announces that OncBioMune Chief Executive Officer Dr. Jonathan Head will be making an abstract poster presentation today at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The conference is being hosted at the Sheraton New York Times Square Hotel in New York, New York from September 25-28.
Dr. Head is scheduled to make the presentation titled, “Phase 1 clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients,” during the Reception and Poster Session A from 5:00-7:30 PM ET today at New York Hilton Midtown, Americas Halls I & II.
Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.

MARKETS

Markets
TSX19692.92+236.21
TSXV646.04+10.63
DOW32823.77-21.36
S&P 5004118.09-12.20
NASD12359.15-31.54
ASX6945.20+55.50

COMMODITIES

Commodities
Gold1767.79+5.92
Silver20.27+0.07
Copper3.52-0.05
Palladium2191.00+89.00
Platinum908.00+11.00
Oil93.83-4.79
Heating Oil3.43-0.12
Natural Gas8.27+0.04

DOWNLOAD FREE REPORTS

×